Business Context and Reporting Period
Company: InMed Pharmaceuticals Inc. (Nasdaq: INM)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended March 31, 2026
Business Overview: InMed is a pharmaceutical drug development company focusing on proprietary small molecule drug candidates targeting diseases with high unmet medical needs (Alzheimer's, dry AMD, Epidermolysis Bullosa). The Company also operates a subsidiary, BayMedica, which commercializes bulk rare cannabinoids.
Key Financial Metrics
| Metric (USD) | Three Months Ended March 31, 2026 |
Nine Months Ended March 31, 2026 |
Nine Months Ended March 31, 2025 |
|---|---|---|---|
| Revenue (Continuing Ops) | $0 | $0 | $0 |
| Revenue (Discontinued Ops) | $659,848 | $2,600,157 | $3,637,923 |
| Total Operating Expenses | $2,839,521 | $6,745,993 | $6,608,338 |
| Net Loss (Continuing Ops) | $(2,791,751) | $(6,530,079) | $(6,855,692) |
| Net Loss (Discontinued Ops) | $(174,585) | $(191,379) | $481,870 (Income) |
| Total Net Loss | $(2,966,336) | $(6,721,458) | $(6,373,822) |
| Cash and Cash Equivalents | $5,158,932 (as of March 31, 2026) | ||
| Short-term Investments | $41,625 (as of March 31, 2026) | ||
| Total Liabilities | $2,242,032 (as of March 31, 2026) | ||
| Accumulated Deficit | $(123,959,350) (as of March 31, 2026) |
Material Changes vs. Prior Period
- Discontinued Operations: The Company classified its BayMedica commercial segment as discontinued operations following a March 4, 2026 board decision to wind down the business due to anticipated U.S. legislation impacting its inventory. This resulted in a loss of $191,379 for the nine months ended March 31, 2026, compared to income of $481,870 in the prior year period.
- Operating Expenses: Total operating expenses for continuing operations increased by 36% ($755,000) in the three months ended March 31, 2026, compared to the prior year. This was driven primarily by a 141% increase in Research and Development (R&D) expenses ($1.02M vs $0.43M) due to higher external contractor and supply costs.
- Financing Activity: Net cash provided by financing activities dropped significantly to $94,497 for the nine months ended March 31, 2026, compared to $4.1 million in the prior year. Proceeds were limited to $231,675 from the Standby Equity Purchase Agreement (SEPA), whereas the prior year included $4.4 million from private placements and SEPA.
- Liquidity: Cash and cash equivalents decreased by approximately $5.6 million during the nine-month period, leaving the Company with approximately $5.2 million in total liquid assets as of March 31, 2026.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Uncertainty
Management has concluded there is substantial doubt about the Company's ability to continue as a going concern for one year following the issuance of these financial statements. The Company expects its current cash of $5.2 million to fund operations only into the fourth quarter of calendar 2026. Future viability depends on raising additional capital.
Strategic Outlook
- Wind Down: BayMedica intends to complete the wind-down of commercial operations by June 30, 2026. Expected severance and related costs are approximately $670,000, partially offset by product sales profits.
- R&D Pipeline: The Company is focusing exclusively on pharmaceutical candidates:
- INM-901 (Alzheimer's): Targeting a pre-IND meeting in Q3 2026 and Phase 1 initiation in 2027. Recent data showed significant reduction in neuroinflammation in human brain organoid models.
- INM-089 (Dry AMD): Planning for a pre-IND meeting in Q4 2026.
- INM-755 (Epidermolysis Bullosa): Pursuing strategic partnerships following positive Phase 2 results.
Material Risks and Contingencies
- Nasdaq Delisting Notice: On March 27, 2026, the Company received notice that its share price fell below the $1.00 minimum bid price requirement. It has 180 days to regain compliance or face delisting, which could severely impact liquidity and financing ability.
- Legal Proceedings (Patent License Matter): BayMedica is involved in arbitration with a third-party licensor. The licensor seeks approximately $3.4 million in past payments and $2.3 million annually for the remainder of the term. An unfavorable outcome could have a material adverse impact on the Company.
- Subsequent Events: In April 2026, the Company amended the exercise prices of approximately 2.3 million Preferred Investment Options from ~$2.44 to $0.80.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $5.2 million cash balance to fund operations through Q4 2026, given the cessation of BayMedica revenue.
- Capital Raising: Assess the likelihood and terms of future equity or debt financing required to sustain operations beyond late 2026.
- Delisting Status: Monitor the Company's progress in curing the Nasdaq minimum bid price deficiency within the 180-day grace period.
- Legal Exposure: Review the status of the arbitration regarding the Patent License Matter and the potential liability of up to $5.7 million plus ongoing annual payments.
- Wind-Down Costs: Confirm actual severance and exit costs for BayMedica against the estimated $670,000.